BR112012029064A2 - formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan - Google Patents

formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan

Info

Publication number
BR112012029064A2
BR112012029064A2 BR112012029064A BR112012029064A BR112012029064A2 BR 112012029064 A2 BR112012029064 A2 BR 112012029064A2 BR 112012029064 A BR112012029064 A BR 112012029064A BR 112012029064 A BR112012029064 A BR 112012029064A BR 112012029064 A2 BR112012029064 A2 BR 112012029064A2
Authority
BR
Brazil
Prior art keywords
hmg
irbesartan
coa reductase
pharmaceutical formulation
reductase inhibitors
Prior art date
Application number
BR112012029064A
Other languages
English (en)
Other versions
BR112012029064B1 (pt
BR112012029064B8 (pt
Inventor
Jae Hyun Park
Jong Soo Woo
Min Jung Kim
Yong Ii Kim
Young Jun Na
Young-Hun Kim
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45395310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012029064(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of BR112012029064A2 publication Critical patent/BR112012029064A2/pt
Publication of BR112012029064B1 publication Critical patent/BR112012029064B1/pt
Publication of BR112012029064B8 publication Critical patent/BR112012029064B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steering Devices For Bicycles And Motorcycles (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan é fornecida uma formulação farmacêutica sob a forma de comprimidos de duas camadas que consiste em uma primeira camada contendo irbesartan ou seus sais farmaceuticamente aceitáveis e uma segunda camada contendo um inibidor da hmg-coa redutase e um aditivo de base, o que pode melhorar a taxa de dissolução e estabilidade de irbesartan e um inibidor da hmg-coa redutase para melhorar a biodisponibilidade do fármaco em comparação com formulações convencionais de complexos e para minimizar a produção de compostos afins, sendo assim eficazmente utilizado como um agente terapêutico superior e estável para a hipertensão e hipercolesterolemia.
BR112012029064A 2010-05-14 2011-05-13 formulação farmacêutica na forma de comprimido de duas camadas compreendendo irbesartan e inibidores da hmgcoa redutase, e seu método de preparação BR112012029064B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20100045636 2010-05-14
KR1020100053782A KR101248804B1 (ko) 2010-05-14 2010-06-08 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
PCT/KR2011/003549 WO2011142621A2 (en) 2010-05-14 2011-05-13 Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan

Publications (3)

Publication Number Publication Date
BR112012029064A2 true BR112012029064A2 (pt) 2016-08-09
BR112012029064B1 BR112012029064B1 (pt) 2019-10-22
BR112012029064B8 BR112012029064B8 (pt) 2020-08-11

Family

ID=45395310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012029064A BR112012029064B8 (pt) 2010-05-14 2011-05-13 formulação farmacêutica na forma de comprimido de duas camadas compreendendo irbesartan e inibidores da hmgcoa redutase, e seu método de preparação

Country Status (36)

Country Link
US (1) US20130028974A1 (pt)
EP (1) EP2568972B1 (pt)
JP (1) JP5969466B2 (pt)
KR (2) KR101248804B1 (pt)
CN (1) CN103002883B (pt)
AR (1) AR081032A1 (pt)
AU (2) AU2011251085A1 (pt)
BR (1) BR112012029064B8 (pt)
CA (1) CA2798363C (pt)
CL (1) CL2012003185A1 (pt)
CO (1) CO6592025A2 (pt)
CR (1) CR20120545A (pt)
DK (1) DK2568972T3 (pt)
DO (1) DOP2012000264A (pt)
EA (1) EA023959B1 (pt)
EC (1) ECSP12012224A (pt)
ES (1) ES2645726T3 (pt)
GT (1) GT201200309A (pt)
HK (1) HK1181685A1 (pt)
HU (1) HUE036638T2 (pt)
IL (1) IL223012B (pt)
JO (1) JO3409B1 (pt)
MA (1) MA34313B1 (pt)
MX (1) MX342868B (pt)
MY (1) MY157307A (pt)
NI (1) NI201200170A (pt)
NZ (1) NZ604402A (pt)
PE (2) PE20151905A1 (pt)
PL (1) PL2568972T3 (pt)
PT (1) PT2568972T (pt)
SG (1) SG185778A1 (pt)
SI (1) SI2568972T1 (pt)
TW (1) TW201200166A (pt)
UA (1) UA107967C2 (pt)
WO (1) WO2011142621A2 (pt)
ZA (1) ZA201209481B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103356500A (zh) * 2012-03-30 2013-10-23 肖广常 一种瑞舒伐他汀钙非诺贝特酸胆碱盐择时渗透泵控释片及其制备方法
BR102012020648A2 (pt) * 2012-08-17 2014-12-09 Hypermarcas S A Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR101502031B1 (ko) * 2013-03-14 2015-03-12 보령제약 주식회사 약제학적 복합제제
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101771766B1 (ko) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
CN105769793A (zh) * 2016-04-04 2016-07-20 孙爱华 一种辛伐他汀片剂及其制备方法
MX2021007734A (es) * 2018-12-31 2021-08-05 Boryung Pharm Comprimido y metodo de preparacion del mismo.
KR102042626B1 (ko) * 2019-06-26 2019-11-11 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
WO2022260439A1 (ko) * 2021-06-09 2022-12-15 주식회사 보령 약학적 복합 제제 및 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003073270A (ja) * 2001-08-30 2003-03-12 Nisshin Seiyaku Kk 安定性および溶出性の良好なプラバスタチンナトリウム錠
AU2002242676B2 (en) * 2002-01-16 2008-05-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
AU2002356419A1 (en) * 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
KR20070104447A (ko) * 2005-02-10 2007-10-25 라이프사이클 파마 에이/에스 페노피브레이트 및 ＨＭＧ-ＣｏＡ 리덕타제 억제제의 고정용량 배합물을 포함하는 안정한 약학 조성물
AU2006306420A1 (en) * 2005-10-25 2007-05-03 Merck Sharp & Dohme Corp. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
WO2008010008A2 (en) * 2006-07-17 2008-01-24 Wockhardt Limited Cardiovascular combinations using rennin-angiotensin inhibitors
AU2007314795B2 (en) * 2006-10-30 2012-02-16 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
KR101205633B1 (ko) * 2008-04-29 2012-11-27 한올바이오파마주식회사 심혈관계 질환 치료용 약제학적 제제
CN102065847A (zh) * 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
CN101590231A (zh) * 2008-05-29 2009-12-02 北京奥萨医药研究中心有限公司 血管紧张素ⅱ受体拮抗剂、他汀类降脂药和烟酸的药物组合物及其用途
CZ301299B6 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem

Also Published As

Publication number Publication date
IL223012B (en) 2019-03-31
MY157307A (en) 2016-05-31
PE20130204A1 (es) 2013-03-11
CN103002883B (zh) 2015-08-26
SI2568972T1 (sl) 2017-10-30
PL2568972T3 (pl) 2017-12-29
CA2798363A1 (en) 2011-11-17
TW201200166A (en) 2012-01-01
EP2568972B1 (en) 2017-08-02
PE20151905A1 (es) 2016-01-07
WO2011142621A3 (en) 2012-03-08
MX2012013175A (es) 2013-01-17
DK2568972T3 (da) 2017-11-06
ECSP12012224A (es) 2012-11-30
AR081032A1 (es) 2012-05-30
NI201200170A (es) 2013-05-29
CR20120545A (es) 2012-12-06
UA107967C2 (en) 2015-03-10
EA201291247A1 (ru) 2013-04-30
JO3409B1 (ar) 2019-10-20
HUE036638T2 (hu) 2018-07-30
NZ604402A (en) 2015-02-27
SG185778A1 (en) 2013-01-30
KR20110126020A (ko) 2011-11-22
EP2568972A2 (en) 2013-03-20
ZA201209481B (en) 2014-02-26
BR112012029064B1 (pt) 2019-10-22
EA023959B1 (ru) 2016-07-29
DOP2012000264A (es) 2012-11-30
IL223012A0 (en) 2013-02-03
CA2798363C (en) 2018-06-05
MX342868B (es) 2016-10-17
CN103002883A (zh) 2013-03-27
BR112012029064B8 (pt) 2020-08-11
MA34313B1 (fr) 2013-06-01
HK1181685A1 (zh) 2013-11-15
AU2016203739B2 (en) 2017-11-02
JP5969466B2 (ja) 2016-08-17
AU2011251085A1 (en) 2013-01-10
JP2013526516A (ja) 2013-06-24
EP2568972A4 (en) 2014-07-02
AU2016203739A1 (en) 2016-06-23
KR101248804B1 (ko) 2013-03-29
KR20130024940A (ko) 2013-03-08
GT201200309A (es) 2014-03-14
PT2568972T (pt) 2017-10-09
CL2012003185A1 (es) 2013-02-22
CO6592025A2 (es) 2013-01-02
WO2011142621A2 (en) 2011-11-17
US20130028974A1 (en) 2013-01-31
ES2645726T3 (es) 2017-12-07

Similar Documents

Publication Publication Date Title
BR112012029064A2 (pt) formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
BR112012024019A2 (pt) forma de dosagem de liberação controlada, e, método para liberar uma droga
PE20140252A1 (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
AR073077A1 (es) Uso de dabigatran. compuesto. composicion farmaceutica-
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP10010167A (es) Composiciones oftálmicas novedosas
AR082660A1 (es) Composiciones farmaceuticas para el tratamiento de enfermedades respiratorias e inflamatorias
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
AR063027A1 (es) Derivados de sulfonamida
BR112015004091A2 (pt) formulação de cápsula de compósito farmacêutico que compreende irbesartan e inibidor de hmg-coa redutase
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
PE20150935A1 (es) Formulacion de comprimido compuesto de dos capas que comprende atorvastatina, irbesartan y carbonato de magnesio
CL2008003584A1 (es) Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva.
AR059081A1 (es) Composicion farmaceutica estable de carisoprodol y meloxicam
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
TH126521A (th) สูตรทางเภสัชกรรมในรูปยาเม็ดสองชั้นที่ประกอบรวมด้วย hmg-coaรีดัคเทส อินฮิบิเตอร์ และเออร์เบซาร์แทน
CO6280050A1 (es) Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2546 DE 22/10/2019 QUANTO AO INVENTOR.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2722 DE 07-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.